Barbexaclone
From Wikipedia, the free encyclopedia
Barbexaclone
|
|
Systematic (IUPAC) name | |
(-)-N,α-Dimethylcyclohexaneethylammonium.5-ethyl-5-phenyl-barbiturate | |
Identifiers | |
CAS number | |
ATC code | N03 |
PubChem | |
Chemical data | |
Formula | C22H33N3O3 |
Mol. mass | 387.52 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Barbexaclone (marketed in Italy as Maliasin by Abbott Laboratories) is a salt compound of phenobarbital and propylhexedrine. It was introduced in 1983. It is reported to be as effective as phenobarbital but better tolerated. 100 mg of barbexaclone is equivalent to 60 mg of phenobarbital. It is not available on prescription in Belgium, Germany, the Netherlands, the UK or the U.S.
[edit] References
- The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8
|